Chiome Bioscience Inc.
4583.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.59 | -3.64 | -0.07 | 0.56 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -31.35 | -32.70 | -31.25 | -140.32 |
| Quality | ||||
| ROIC | -19.39% | -14.84% | -12.61% | -4.87% |
| Gross Margin | 55.33% | 51.48% | 58.14% | 59.52% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 0.32% | 2.62% | 14.80% | 30.34% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 3.61 | 4.46 | 5.82 | 16.25 |
| Interest Coverage | -280.00 | -263.06 | -292.33 | -132.26 |
| Efficiency | ||||
| Inventory Turnover | 0.99 | 1.18 | 1.21 | 3.14 |
| Cash Conversion Cycle | 90.09 | 60.27 | 63.21 | 24.61 |